The Demand for Global Metastasis Cancer Treatment Market, In Terms Of Revenue, Was Worth of USD 63.18 Billion in 2020 and is expected to reach USD 161.67 Billion in 2027, growing at global Metastasis cancer treatment CAGR of 12.3% from 2021 to 2027.
Metastasis cancer represents the advanced form of cancer, which occurs when the cancer cells start spreading from the site of origin to different parts of the body. Treatment for Metastasis cancer aims to slow the expansion or spread of the cancer. Treatment depends on the sort of cancer, where it started, the dimension and location of the metastasis and other factors. The treatment for Metastasis cancer is often different from the ones used for a normal tumor. Treatment of Metastasis cancer is often not curable and is mainly focused on providing relaxing care. Several manufactures are investing in oncology market and are making vigorous efforts for the supply of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to capture their condition, which is turn, is increasing the adoption rate of the Metastasis cancer treatment drugs.
The major drivers for the global Metastasis cancer treatment market growth are rising prevalence of cancer and high medical needs of patients who have Metastasis cancer. Rising prevalence of Metastasis cancer is one of the major factors expected to drive the growth of the global Metastasis cancer treatment market. It is estimated that metastasis is responsible for about 90% of cancer deaths. This estimate has changed little in more than 50 years, according to National Center for Biotechnology Information. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. Breast cancer is the second most common cause of death from cancer in 6% women. It is estimated that 42,690 people will die from breast cancer, according to American Society of Clinical Oncology. Metastasis breast cancer will cause the vast majority of those deaths. However, high cost of Metastasis cancer treatment may hamper the growth of this market. In spite of that, increasing number of pharmaceutical, biotechnology and diagnostic companies are focusing on research and development of innovative oncology medicines to provide advanced treatment which may create more opportunities for the further growth of the market.
The study provides a crucial view of global Metastasis cancer treatment market by segmenting the market based on the basis of product type, therapeutic indication and region & country level. On the basis of product type, global Metastasis cancer treatment market is segmented as branded medicines and generic medicines. On the basis of therapeutic indication, the market is segmented into breast cancer, melanoma, lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, liver cancer and others. The regions covered in global Metastasis cancer treatment market are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global Metastasis cancer treatment market is sub divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.
The product type segment of Metastasis cancer treatment market is dominated by Branded Medicines by capturing the largest market share XX.XX% in year 2020. The Therapeutic indication segment of global Metastasis cancer treatment market is dominated by Breast cancer by capturing the largest market share 26.91% in year 2020.
North America is the highest revenue generating market for Metastasis cancer treatment solutions. The rate of diagnosis is high in this region due to advances healthcare infrastructure and awareness among the people. According to American cancer society; in 2016; there were approximately 3.5 million women living with an antiquity of breast cancer in the United States. More than 16.9 million Americans with a history of cancer were alive on January 1st, 2019, and this number is projected to grow to more than 22.1 million by January 1st, 2030, according to Carevive Systems, Inc. Europe is second largest region for this market due to rising Advancements in immune-oncology and precision medicine. Immense scientific innovation in the field of oncology has resulted in higher regulatory approval rates of cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy, among others in this region. In 2017, more than 3,500 radiation therapy machines were used by hospitals and providers of ambulatory health care in the European Union (EU). The performance of breast-protection surgery has increased, and the use of neoadjuvant therapy to downstage locally advanced breast cancer has become more common in the Asia–Pacific region.
Metastasis cancer is one of the major concerns in today’s life owing to the rising prevalence of cancer and its fast progression coupled with high mortality rate. To overcome the risk of Metastasis cancer the government is taking initiatives in increase awareness among people and encouraging people for annual health checkup which helps in the early detection of cancer. Moreover, there are numerous market players accelerating their research on cancer-related treatment and drugs which slow down the progression. In 2020 around 20 cancer drugs are approved by the FDA as mentioned below.
Lapatnib tablets are used for the treatment of Advanced or Metastasis breast cancer in United States. The company has launched Lapatnib tablets with a strength of 250 mg after final approval of a new drug application (ANDA) abbreviated from the United States by alliance partner Natco Pharma.
Atezolizumab: Atezolizumab (a cancer-related drug) in combination with NAB-paclitaxel (chemotherapy) is used for the first-line treatment for TNBC patients. Roche’s Atezolizumab receives DCGI approval for treatment of Metastasis triple-negative breast cancer in India.
Zirabev: The Zirabev drug was launched in 2020 and it is available for the treatment of 5 types of cancer: Metastasis colorectal cancer; unresectable, locally advanced, recurrent or Metastasis non-squamous non-small cell lung cancer; recurrent glioblastoma; Metastasis renal cell carcinoma; and persistent, recurrent or Metastasis cervical cancer.
The huge product pipeline of various market players for oncology will led to continuous product launches in the market but apart from drug launch there are few other treatment options developing over the period of time for the treatment of Metastasis cancer.
Precision Medicine: Increasing recent advancements in the field of precision medicine coupled with the technological advancement are the important factors which helps to trend in market. Precision medicine is an approach to patient care that allows doctors to choose the treatment that helps patients according to their genetic understanding of the disease. It is also known as personalized medicine. Additionally, Precision medicine is based on knowing the effects of certain gene mutations. For example, Rozlytrek (entrectinib) became the third cancer treatment approved by the FDA based on a commonly expressed biomarker.
Combination drug/combined chemotherapy: In combined chemotherapy, more than one drug is used in some or the other form to treat cancer. The constant increase in R&D has proved that combined chemotherapy is much more effective and has reduced side effects as compared to the conventional chemotherapy drugs. For example, Tukysa is used in combination with trastuzumab and capecitabine which is approved in April 2020 by FDA. It is intended for adults with advanced Metastasis HER2-positive breast cancer, including cancer that has spread to the brain and is difficult to treat.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 63.18 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||12.30 %|
|Market Size Expected in 2027:||USD 161.67 Billion|
|Tables, Charts & Figures:||175|
AbbVie, Inc., Amgen, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, BRISTOL-MYERS SQUIBB COMPANY, Eli-Lilly and Company, Hoffmann-La Roche AG, JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., SANOFI, Others
|Segments Covered||By-Products, By Therapeutic Indication|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®